Answers are grounded in this paper and cite their sources.
Our early-phase data suggested that children with neurofibromatosis type 1 and inoperable plexiform neurofibromas benefited from long-term dose-adjusted treatment with selumetinib without having excess toxic effects. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT01362803 .).
No takes yet. Share an insight, caveat, or question.
Dombi et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: